| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| No holdings reported for quarter Q1 2016 | ||||||||
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ESSA PHARMA INC | 19 | Q2 2024 | 10.8% |
| IRADIMED CORP | 19 | Q2 2024 | 5.8% |
| SURMODICS INC | 17 | Q2 2024 | 4.7% |
| XENON PHARMACEUTICALS INC | 16 | Q4 2023 | 2.9% |
| NOVOCURE LTD | 16 | Q2 2024 | 3.4% |
| BIOATLA INC | 15 | Q2 2024 | 29.1% |
| C4 THERAPEUTICS INC | 15 | Q2 2024 | 5.2% |
| KRYSTAL BIOTECH INC | 15 | Q2 2024 | 2.5% |
| NATERA INC | 15 | Q2 2024 | 3.9% |
| AXOGEN INC | 15 | Q2 2024 | 2.2% |
View Soleus Capital Management, L.P.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-08-20 |
| 13F-HR | 2024-08-14 |
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View Soleus Capital Management, L.P.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.